Literature DB >> 3089574

Growth hormone therapy in Canada: end of one era and beginning of another.

H J Dean, H G Friesen.   

Abstract

This paper reviews the difficulties in diagnosing a true deficiency of growth hormone (GH), the long-term results of therapy, the Canadian experience in treating GH deficiency, including the contributions made by the Medical Research Council's Therapeutic Trial of Human Growth Hormone, and the occurrence of Creutzfeldt-Jakob disease in recipients of GH therapy. It also speculates on potential alternatives to treatment with GH derived from human pituitaries.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089574      PMCID: PMC1491444     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  33 in total

1.  Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee.

Authors:  C J Gibbs; D C Gajdusek; D M Asher; M P Alpers; E Beck; P M Daniel; W B Matthews
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

2.  Report of the conference on uses and possible abuses of biosynthetic human growth hormone.

Authors:  L E Underwood
Journal:  N Engl J Med       Date:  1984-08-30       Impact factor: 91.245

3.  Final height of patients with pituitary growth failure and changes in growth variables after long term hormonal therapy.

Authors:  E Joss; K Zuppinger; H P Schwarz; H Roten
Journal:  Pediatr Res       Date:  1983-08       Impact factor: 3.756

4.  Creutzfeldt-Jakob disease after administration of human growth hormone.

Authors:  J Powell-Jackson; R O Weller; P Kennedy; M A Preece; E M Whitcombe; J Newsom-Davis
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

5.  The educational, vocational, and marital status of growth hormone-deficient adults treated with growth hormone during childhood.

Authors:  H J Dean; T L McTaggart; D G Fish; H G Friesen
Journal:  Am J Dis Child       Date:  1985-11

6.  Treatment of idiopathic pituitary dwarfism with methionyl human growth hormone.

Authors:  K Takano; K Shizume; N Hizuka; I Hibi; K Kato; H Kohno; T Kondo; M Ogawa; Y Okada; M Sudo
Journal:  Endocrinol Jpn       Date:  1983-08

7.  Children with normal-variant short stature: treatment with human growth hormone for six months.

Authors:  D Rudman; M H Kutner; R D Blackston; R A Cushman; R P Bain; J H Patterson
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

8.  Growth enhancement by dopaminergic therapy in children with intrauterine growth retardation.

Authors:  C A Huseman
Journal:  J Clin Endocrinol Metab       Date:  1985-09       Impact factor: 5.958

9.  Comparative study of serum human growth hormone measurement with NB2 lymphoma cell bioassay, IM-9 receptor modulation assay, and radioimmunoassay in children with disorders of growth.

Authors:  E Tokuhiro; H J Dean; H G Friesen; D Rudman
Journal:  J Clin Endocrinol Metab       Date:  1984-03       Impact factor: 5.958

10.  The effect of growth hormone treatment on somatomedin levels in growth hormone-deficient children.

Authors:  H J Dean; J G Kellett; R M Bala; H J Guyda; B Bhaumick; B I Posner; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

View more
  3 in total

Review 1.  Creutzfeldt-Jakob disease: the Canadian situation.

Authors:  E Stratton
Journal:  CMAJ       Date:  1997-11-15       Impact factor: 8.262

2.  Creutzfeldt-Jakob disease in Canada. Laboratory Centre for Disease Control.

Authors: 
Journal:  Can Fam Physician       Date:  1996-11       Impact factor: 3.275

3.  The epidemiology of Creutzfeldt-Jakob disease in Canada: a review of mortality data.

Authors:  E Stratton; M N Ricketts; P R Gully
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.